BridgeBio Pharma shares fall 1.95% after-hours following an investor webinar announcement.

Wednesday, Sep 3, 2025 4:18 pm ET1min read
Bridgebio Pharma, Inc. declined 1.95% in after-hours trading, following the announcement that the company will host an investor webinar on September 10, 2025, featuring Dr. Rachel Gafni, who will provide an overview of autosomal dominant hypocalcemia type 1 (ADH1) and the Company’s Phase 3 clinical trial, CALIBRATE.

Comments



Add a public comment...
No comments

No comments yet